Fig. 1 · Structure

Documents & Downloads

NU 6102

Cat. No. A12438 CAS 444722-95-6

CDK inhibitor

NU6102 is selective for CDK1 and CDK2 compared to CDK4/D1 (IC50=1.6 μM), DYRK1A (IC50=0.9 μM), PDK1 (IC50=0.8 μM) and ROCKII (IC50=0.6 μM).

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
Cdk1/cyclin B IC50 9.5 nM
CDK2/cyclin A3 IC50 5.4 nM
CDK4 IC50 1.6 μM
DYRK1A IC50 0.9 μM
PDK1 IC50 0.8 μM

Cellular Effect

Cell Line Activity Value Description Reference
Sf9 IC50 0.022 μM Inhibition of His-tagged CDK2/cyclin E (unknown origin) expressed in Baculovirus infected Sf9 cells using histone H1 as substrate in presence of [gamma-33P]-ATP by radiometric filter binding assay [PMID: 30234987]
Sf9 IC50 0.117 μM Inhibition of GST-tagged CDK5/p25 (unknown origin) expressed in Baculovirus infected Sf9 cells using histone H1 as substrate as substrate in presence of [gamma-33P]-ATP by radiometric filter binding assay [PMID: 30234987]
Sf9 IC50 0.146 μM Inhibition of His-tagged CDK1/cyclin B1 (unknown origin) expressed in Baculovirus infected Sf9 cells using histone H1 as substrate in presence of [gamma-33P]-ATP by radiometric filter binding assay [PMID: 30234987]
Sf9 IC50 0.184 μM Inhibition of GST-tagged CDK4/cyclin D1 (unknown origin) expressed in Baculovirus infected Sf9 cells using RPPTLSPIPHIPR peptide as substrate in presence of [gamma-33P]-ATP by radiometric filter binding assay [PMID: 30234987]
Sf9 IC50 2.5 μM Inhibition of GST-tagged CDK7/cyclinH/MAT1 (unknown origin) expressed in Baculovirus infected Sf9 cells using YSPTSPS-2 KK peptide as substrate as substrate in presence of [gamma-33P]-ATP by radiometric filter binding assay [PMID: 30234987]
Sf9 IC50 4.1 μM Inhibition of GST-tagged CDK9/CyclinT1 (unknown origin) expressed in Baculovirus infected Sf9 cells using YSPTSPS-2 KK peptide as substrate as substrate in presence of [gamma-33P]-ATP by radiometric filter binding assay [PMID: 30234987]

NU 6102 Research Summary

This section summarizes 4 in vitro studies of NU 6102 from 3 published references. In vitro models include HCT116; asynchronously cycling HCT-116 TICRR-mClover cells.

NU 6102 In Vitro Studies

NU 6102 yielded GI50 values of 5.7±0.4 μM in HCT116 cells and 13.3±3.4 μM in HT29 cells after incubation for 72 h. In asynchronously cycling HCT-116 TICRR-mClover cells, treatment at 20uM for 2 h decreased bulk TICRR protein levels, assessed by capillary electrophoresis. In primary cells derived from late-stage HGSC clinical samples and cell line models, NU 6102 showed no activity in the live cell viability readout (IC50 > 10 μM). [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Growth inhibition in HCT116 cells

Cell-based study · HCT116 [1]

HCT116 cells were incubated with the compound for 72 h. The GI50 was 5.7±0.4 μM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
50% growth inhibition (GI50)GI50 5.7±0.4 μM[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.001–100 μM
Exposure duration
72 h
Method
incubated
Vehicle
DMSO with a final DMSO concentration of 1% (v/v)
Methods and source locations

Compound reported in the paper: NU 6102

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Cell growth inhibition assays (S12, S13, S14, S15); Table 2 (T2.h1, T2.r11)

50% growth inhibition (GI50): 50% growth inhibition (GI50); comparator: cells exposed to 1% (v/v) DMSO — Materials and methods > Cell growth inhibition assays (S15); Table 2 (T2.h1, T2.r11)

TICRR protein decrease in asynchronously cycling cells

Cell-based study · asynchronously cycling HCT-116 TICRR-mClover cells [2]

Asynchronously cycling HCT-116 TICRR-mClover cells received 20uM of the compound in the culture medium for 2 h. Capillary electrophoresis showed a decrease in bulk TICRR protein levels.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
TICRR protein levels by capillary electrophoresisReported result a decrease in bulk TICRR protein levels[2]

Literature-Reported Treatment Conditions

Treatment concentration
20uM
Exposure duration
2 h
Method
added to the cell culture medium
Reported limits
Not stated in the sentences used: vehicle, control.
Methods and source locations

Compound reported in the paper: NU 6102

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

MATERIALS AND METHODS > Cell culture (S7); RESULTS > CDK1/2 inhibition promotes TICRR protein degradation during S phase (S192, S193); Figure 9. legend (S319)

TICRR protein levels by capillary electrophoresis: TICRR protein levels by capillary electrophoresis — RESULTS > CDK1/2 inhibition promotes TICRR protein degradation during S phase (S192, S193)

Viability assessment in HGSC models

Cell-based study · primary cells derived from late-stage HGSC clinical samples and cell line models [3]

The compound was evaluated for live cell viability in primary cells derived from late-stage HGSC clinical samples and cell line models. It showed no activity (IC50 > 10 μM).

Measured endpoints — not treatment concentrations
EndpointReported resultReference
live cell viabilityIC50 IC50 > 10 μM[3]

Literature-Reported Treatment Conditions

Reported limits
Not stated in the sentences used: dose, route, schedule, vehicle.
Methods and source locations

Compound reported in the paper: NU 6102

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > Compounds, cell culture and cell viability assays (S44, S48); Results > Validation of predicted HGSC-specific therapeutics (S113, S117, S118)

live cell viability: live cell viability; comparator: vehicle control and Staurosporine positive control — Methods > Compounds, cell culture and cell viability assays (S44); Results > Validation of predicted HGSC-specific therapeutics (S118)

Growth inhibition in HT29 cells

Cell-based study · HT29 [1]

HT29 cells were incubated with the compound for 72 h. The GI50 was 13.3±3.4 μM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
50% growth inhibition (GI50)GI50 13.3±3.4 μM[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.001–100 μM
Exposure duration
72 h
Method
incubated
Vehicle
DMSO with a final DMSO concentration of 1% (v/v)
Methods and source locations

Compound reported in the paper: NU 6102

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Cell growth inhibition assays (S12, S13, S14, S15); Table 2 (T2.h1, T2.r11)

50% growth inhibition (GI50): 50% growth inhibition (GI50); comparator: cells exposed to 1% (v/v) DMSO — Materials and methods > Cell growth inhibition assays (S15); Table 2 (T2.h1, T2.r11)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 444722-95-6
Applications CDK inhibitor
Formula C18H22N6O3S
Molecular Weight 402.5
SMILES
C1CCC(CC1)COC2=NC(=NC3=C2NC=N3)NC4=CC=C(C=C4)S(=O)(=O)N

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

NU 6102 Research References

  1. [1] Beale G, Haagensen EJ, Thomas HD, et al. Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancer. Br J Cancer (2016). PMID: 27529512 DOI: 10.1038/bjc.2016.238 Source material
  2. [2] Wittig KA, Sansam CG, Noble TD, et al. The CRL4DTL E3 ligase induces degradation of the DNA replication initiation factor TICRR/TRESLIN specifically during S phase. Nucleic Acids Res (2021). PMID: 34534348 DOI: 10.1093/nar/gkab805 Source material
  3. [3] Quintela M, James DW, Garcia J, et al. In silico enhancer mining reveals SNS-032 and EHMT2 inhibitors as therapeutic candidates in high-grade serous ovarian cancer. Br J Cancer (2023). PMID: 37120667 DOI: 10.1038/s41416-023-02274-2 Source material

Added to your cart

View Cart Checkout
Loading...